AXSM Axsome Therapeutics, Inc.
$143.97▼ -0.06%
Healthcare
Other
Volume 95.1K
Avg Volume (10D) 916.9K
Key Metrics & Fundamentals
Market Cap
$7.54B
P/E Ratio
–
Div Yield
0.00%
52W Range
123.50 - 260.19
% vs 50 MA
-24.36%
% vs 200 MA
-27.95%
RSI-14
21.1
MACD Histogram
-0.8500
Beta (1Y vs SPY)
0.57
Free Cash Flow
-$33.40M
Gross Rev
$218.38M
Gross Profit
$204.81M
EBITDA
-$48.26M
COGS
$13.56M
Operating Exp
$255.95M
Operating Income
-$51.14M
EBIT
-$51.14M
Pretax Income
-$51.19M
Net Income
-$51.31M
EPS (Diluted)
-0.99
Price & Volume History
Loading chart…
Recent News
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Zacks · Oct 27, 2026 9:00 AM ET
Will Axsome Therapeutics (AXSM) Report Negative Earnings Next Week? What You Should Know
Zacks · Oct 26, 2026 9:00 AM ET
2 Growth Stocks to Hold for the Next Decade (Hint: These Aren’t AI Stocks)
Motley Fool · Oct 23, 2026 4:05 PM ET
Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?
Zacks · Oct 21, 2026 10:00 AM ET
What First Trust NYSE Arca Biotech (FBT) Bought: Tarsus Leads on Oct. 16
GuruFocus.com · Oct 20, 2026 7:04 AM ET
2 Under-the-Radar Stocks to Buy and Hold
Motley Fool · Oct 16, 2026 10:28 AM ET
Does Axsome Therapeutics (AXSM) Trade Above Fair Value On Sales?
Simply Wall St. · Oct 16, 2026 9:09 AM ET
Axsome Shows Valuation Disconnect Ahead of Q3, RBC Says
MT Newswires · Oct 14, 2026 11:10 AM ET
Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For?
Insider Monkey · Oct 13, 2026 1:42 PM ET
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?
Zacks · Oct 13, 2026 9:01 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See AXSM's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.